Buy Clomid (Clomiphene Citrate 25mg / 50mg / 100mg) Online - Original Sanofi Brand Cipla and Sunrise Remedies Generic SERM Fertility Therapy
Clomid (Clomiphene Citrate 25mg / 50mg / 100mg) represents the original prescription fertility brand name - the world's most widely recognized ovulation induction medication that established Selective Estrogen Receptor Modulator (SERM) therapy for anovulatory infertility. Originally developed by Merrell Dow Pharmaceuticals (later Marion Merrell Dow, subsequently acquired by Sanofi/Aventis) and FDA-approved as Clomid in 1967, clomiphene citrate has over 55 years of continuous clinical use as the foundational first-line fertility medication worldwide. The Clomid brand identity is preserved on rxshop.md through Cipla - one of India's largest pharmaceutical companies with WHO-GMP and US FDA-inspected facilities - and Sunrise Remedies - established Indian pharmaceutical manufacturer. Distinctive advantage of Clomid on rxshop.md is availability in three dose strengths (25 mg, 50 mg, and 100 mg) enabling precise individualized dosing across the full clinical range from sensitive patient starting doses through maximum escalation without tablet splitting or combining.
Clomiphene citrate works as a Selective Estrogen Receptor Modulator (SERM) through paradoxical anti-estrogenic action at the hypothalamus. First, clomiphene binds hypothalamic estrogen receptors as antagonist blocking normal estrogen negative feedback. Second, this increases GnRH (gonadotropin-releasing hormone) pulsatility from the hypothalamus. Third, elevated GnRH stimulates pituitary FSH and LH release promoting ovarian follicular development. Fourth, mature follicles produce estradiol triggering the LH surge and ovulation. Fifth, clomiphene provides predictable ovulation timing approximately 5-10 days after last dose enabling timed intercourse or intrauterine insemination scheduling. Clinical trials demonstrate 60-80 percent ovulation induction and 40-50 percent cumulative pregnancy rate over 6 cycles in appropriate candidates.
Clomid serves comprehensive fertility indications. Primary FDA-approved uses include ovulatory dysfunction, Stein-Leventhal Syndrome (PCOS), secondary amenorrhea, oligomenorrhea, and dysfunctional uterine bleeding. Common off-label uses include unexplained infertility with intrauterine insemination, oligospermia in male hypogonadism, Chiari-Frommel syndrome, and luteal phase deficiency.
Clomid dosed at strength-appropriate 5-day cycles starting cycle day 3-5. Standard 50 mg starting dose with escalation to 100 mg or 150 mg (using 100 mg + 50 mg combination) for non-response. Contraindicated in pregnancy (Category X), liver disease, ovarian cysts, hormone-sensitive cancers, and pituitary tumors. Any visual disturbances require immediate discontinuation. Requires reproductive endocrinology supervision.
Free prescription
Discrete packaging
Have questions?
Quality Assurance
- Stimulation of Ovulation in Anovulatory Cycles: Induces ovulation in cycles where no egg release is occurring naturally;
- Hypothalamic Function Deficiency Ovulation Disorders: Functional hypothalamic amenorrhea with adequate estrogen levels responds to clomiphene stimulation;
- Secondary Amenorrhea Various Etiologies: Absent menstruation with normal anatomy from multiple hormonal causes;
- Oligomenorrhea: Infrequent menstruation with cycles longer than 35 days indicating ovulatory dysfunction;
- Dysfunctional Uterine Bleeding: Abnormal uterine bleeding from anovulatory hormonal imbalance responding to cycle regulation;
- Stein Leventhal Syndrome PCOS: Polycystic ovary syndrome - most common cause of anovulatory infertility responsive to clomiphene;
- Non Cancerous Galactorrhea: Selected use for hormonal galactorrhea after evaluation for pituitary and pathological causes;
- Male Oligospermia Off Label: Off-label use for male hypogonadism to restore testosterone through hypothalamic-pituitary stimulation;
- Chiari Frommel Syndrome: Post-partum amenorrhea-galactorrhea syndrome with prolonged lactation-related anovulation;
- Ovulation Induction Therapy: Comprehensive category for inducing predictable ovulation in fertility treatment protocols;
- Unexplained Infertility Off Label: Off-label empirical use with intrauterine insemination for couples without identifiable infertility cause;
- Luteal Phase Deficiency: Selected use for inadequate corpus luteum function producing progesterone deficiency;
- Superovulation for IUI: Multiple follicle development for intrauterine insemination protocols increasing pregnancy rates;
- First Line Fertility Therapy: Standard initial pharmacological approach before more intensive fertility interventions;
- Timed Intercourse Support: Predictable ovulation timing enables optimal timed intercourse for natural conception attempts;
- SERM Fertility Class Therapy: Selective estrogen receptor modulator specifically for ovulation induction indication;
- Pituitary Gonadotropin Stimulation: Increases pituitary FSH and LH release stimulating ovarian follicular development;
- Menstrual Cycle Regularization: Predictable ovulation restores regular menstrual cycles in anovulatory women;
- Original Clomid Brand Therapy: Bioequivalent Cipla and Sunrise Remedies generic under recognized Clomid brand identity.
- Increases Pregnancy Chances: Restores ovulatory cycles enabling natural or assisted conception with 40-50 percent cumulative pregnancy rate over 6 cycles;
- Treats Polycystic Ovary Syndrome: First-line therapy for PCOS-related anovulation - most common cause of infertility responsive to clomiphene;
- Non Invasive Oral Medication Option: Simple oral tablet therapy without injections or surgical procedures - convenient first-line fertility approach;
- Monitored Treatment with Dosage Adjustments: Three dose strengths enable precise individualized therapy with predictable dose escalation for non-responders;
- Low Risk of Multiples: 8-10 percent twin risk substantially lower than injectable gonadotropins and IVF pregnancy therapies;
- Short Treatment Duration: Only 5 days per cycle simplifies treatment protocol and improves adherence;
- Improves Luteal Phase: Successful ovulation produces natural corpus luteum progesterone supporting adequate luteal phase;
- Normalize Menstrual Cycle: Regular ovulatory cycles restored in majority of anovulatory patients providing hormonal regularization;
- Better Three Strength Flexibility: 25/50/100 mg strengths enable precise dosing across full clinical range without tablet splitting or combining;
- Better Original Brand Heritage: Clomid is the world most recognized fertility brand name with over 55 years continuous clinical use;
- Better Predictable Ovulation Timing: Expected ovulation days 14-16 enables precise timed intercourse or IUI scheduling;
- Better Cost Effective Fertility Therapy: Substantially more affordable than injectable gonadotropins for initial fertility treatment;
- Better Established Safety Profile: Over 55 years of continuous clinical use with well-established safety profile documentation;
- Better Dose Escalation Protocol: Progressive dose escalation from 50 to 100 to 150 mg enables individualized therapy optimization;
- Better Two Manufacturer Options: Cipla and Sunrise Remedies provide bioequivalent generic options with quality manufacturing standards;
- Better 25mg for Sensitive Patients: 25 mg strength enables gentle starting dose for sensitive patients or half-dose protocols;
- Better Empirical Unexplained Infertility Use: Combined with IUI provides pregnancy rate enhancement for unexplained infertility couples;
- Better Reversible Effects: Effects reverse after discontinuation without lasting hormonal disruption after therapy completion;
- Better Quality of Life: Successful pregnancy through effective fertility therapy dramatically improves quality of life for couples struggling with infertility.
Generic Clomid (Clomiphene 25 mg) Medication guide:
Clomid (Clomiphene Citrate 25mg / 50mg / 100mg) represents the original prescription fertility brand name - the world's most widely recognized ovulation induction medication that established Selective Estrogen Receptor Modulator (SERM) therapy for anovulatory infertility. Originally developed by Merrell Dow Pharmaceuticals (later Marion Merrell Dow, subsequently acquired by Sanofi/Aventis) and FDA-approved as Clomid in 1967, clomiphene citrate has over 55 years of continuous clinical use as the foundational first-line fertility medication worldwide. The Clomid brand identity is preserved on rxshop.md through Cipla - one of India's largest pharmaceutical companies with WHO-GMP and US FDA-inspected facilities - and Sunrise Remedies - established Indian pharmaceutical manufacturer. Distinctive advantage of Clomid on rxshop.md is availability in three dose strengths (25 mg, 50 mg, and 100 mg) enabling precise individualized dosing across the full clinical range from sensitive patient starting doses through maximum escalation without tablet splitting or combining. This comprehensive medication guide covers every aspect of Clomid therapy including brand heritage, SERM pharmacology, three-strength dosing flexibility, cycle-based protocols, dose escalation strategy, critical safety warnings including visual disturbances requiring immediate discontinuation, and comprehensive gynecological fertility considerations.
💊 Introduction to Clomid
Clomid is a prescription oral medication containing clomiphene citrate as its active ingredient in tablet form. Clomiphene citrate is a Selective Estrogen Receptor Modulator (SERM) specifically developed for ovulation induction in women with anovulatory infertility. Clomiphene citrate was originally developed by Merrell Dow Pharmaceuticals and received FDA approval as Clomid in 1967. Through subsequent corporate ownership (Merrell Dow → Marion Merrell Dow → Hoechst Marion Roussel → Aventis → Sanofi), the Clomid brand identity has been preserved as the world's most recognized fertility medication brand name with over 55 years of continuous clinical use establishing SERM therapy for ovulation induction.
The Clomid brand available on rxshop.md is manufactured through two established Indian pharmaceutical companies: Cipla - one of India's largest pharmaceutical manufacturers with over 85 years of history, WHO-GMP certification, US FDA-inspected facilities, and extensive international distribution - and Sunrise Remedies - established Indian pharmaceutical manufacturer with comprehensive generic pharmaceutical portfolio. Both manufacturers produce bioequivalent clomiphene citrate under the recognized Clomid brand identity with three dose strengths available.
The distinctive feature of Clomid on rxshop.md is availability in three dose strengths - 25 mg, 50 mg, and 100 mg - providing unprecedented dosing flexibility for individualized fertility therapy. This three-strength availability enables precise dosing across the entire clinical range: 25 mg for sensitive patients requiring gentle starting doses, 50 mg for standard first-line therapy, and 100 mg for escalation therapy in non-responders. Additionally, the 100 mg strength can be combined with the 50 mg strength to achieve 150 mg maximum dose (100 + 50) without requiring tablet splitting or multiple 50 mg tablets, simplifying dosing protocols.
🏭 Two Manufacturer Options
Cipla Limited India
Cipla Limited India credentials:
- Founded 1935 - over 85 years of pharmaceutical manufacturing experience
- One of largest Indian pharmaceutical companies globally
- WHO-GMP certification - highest quality manufacturing standards
- US FDA-inspected facilities meeting American regulatory requirements
- EU-GMP certification serving European market
- Extensive generic portfolio across all major therapeutic categories
- Global presence serving 80 plus countries with generic pharmaceuticals
Sunrise Remedies
Sunrise Remedies credentials:
- Established Indian pharmaceutical manufacturer with generic portfolio
- Quality manufacturing standards ensuring bioequivalent generic quality
- Reproductive medicine specialty with focus on fertility and hormone therapies
- Cost-effective manufacturing enabling accessible therapy pricing
- Regional distribution serving Indian and international markets
Manufacturer Choice Considerations
Both Cipla and Sunrise Remedies produce bioequivalent clomiphene citrate with equivalent expected clinical outcomes. Patient choice may depend on availability, pricing, prior experience, prescriber preference, or specific dose strength availability at each manufacturer. Both formulations undergo bioequivalence testing ensuring equivalent pharmacokinetic delivery of clomiphene citrate to the systemic circulation for equivalent therapeutic effect.
📜 Clomid Brand Heritage
Original Sanofi Brand Timeline
Clomid historical development:
- 1960s: Clomiphene citrate developed by Merrell Dow Pharmaceuticals
- 1967: FDA approval as Clomid - world first oral ovulation induction medication
- 1970s: Establishment as first-line fertility therapy globally
- 1990s: Marion Merrell Dow acquisition and continued development
- 1995: Hoechst Marion Roussel acquisition
- 1999: Aventis formed through Hoechst and Rhone-Poulenc merger
- 2004: Sanofi acquired Aventis creating Sanofi-Aventis (now Sanofi)
- Currently: Sanofi maintains original Clomid brand rights internationally with generic manufacturing under recognized brand identity
Clomid Class-Defining Significance
Clomid launch in 1967 fundamentally transformed reproductive medicine by introducing several unprecedented capabilities:
- First oral ovulation induction medication: Before Clomid, no effective oral fertility drugs existed
- Established SERM class: Foundation for later SERM developments (tamoxifen, raloxifene, ospemifene)
- Democratized fertility treatment: Made fertility therapy accessible without injectable protocols
- Ovulation induction paradigm: Established hypothalamic-pituitary approach vs direct ovarian stimulation
- PCOS treatment cornerstone: Became first-line therapy for most common infertility cause
- Cost-effective fertility care: Substantially lower cost than injectable gonadotropins or IVF
- Global brand recognition: Most widely known fertility medication brand name worldwide
- Continuous 55+ years use: Testament to enduring efficacy and safety profile
🧪 Chemistry and Mechanism
Clomiphene citrate has the chemical formula C26H28ClNO·C6H8O7 with molecular weight approximately 598.1 g/mol. Chemically, clomiphene is a triphenylethylene derivative structurally related to tamoxifen and other early SERMs. The clinical formulation is the citrate salt of clomiphene providing enhanced water solubility and pharmaceutical stability.
Isomer Composition
Clomiphene isomer composition:
- Enclomiphene (approximately 60 percent): Primary antiestrogenic isomer responsible for fertility effect
- Zuclomiphene (approximately 40 percent): Mixed estrogenic and antiestrogenic activity - longer half-life
- Combined effect: Net antiestrogenic hypothalamic effect producing ovulation induction
- Long-acting zuclomiphene: Explains cumulative effects over multiple cycles
Mechanism of Action
Clomiphene mechanism at hypothalamic level:
- Hypothalamic estrogen receptor binding: Clomiphene binds estrogen receptors in hypothalamus as antagonist
- Blocks estrogen negative feedback: Normal estrogen negative feedback on hypothalamus is prevented
- Increased GnRH pulsatility: Hypothalamus perceives low estrogen and increases GnRH release frequency
- Pituitary stimulation: Elevated GnRH stimulates pituitary FSH and LH release
- Ovarian follicular development: Increased FSH stimulates recruitment and growth of ovarian follicles
- Estradiol production: Growing follicles produce increasing estradiol levels
- LH surge triggering ovulation: Peak estradiol triggers pituitary LH surge inducing ovulation
- Predictable ovulation timing: Ovulation occurs approximately 5-10 days after last clomiphene dose
Additional Tissue Effects
Clomiphene has variable effects on other estrogen-responsive tissues that can affect fertility outcomes:
- Cervical mucus: Antiestrogenic effect may thicken cervical mucus reducing sperm penetration
- Endometrium: Antiestrogenic effect may thin endometrium reducing implantation success
- Breast tissue: Mixed effects
- Vaginal epithelium: Mixed effects may cause vaginal dryness
- Bone tissue: Estrogenic protective effect (like other SERMs)
Pharmacokinetic Profile
| Parameter | Value | Clinical Significance |
|---|---|---|
| Oral bioavailability | Well absorbed | Predictable oral therapy |
| Time to peak (Tmax) | 6-8 hours | Peak plasma concentration |
| Half-life (enclomiphene) | Approximately 5-7 days | Sustained hypothalamic effect |
| Half-life (zuclomiphene) | Very long - weeks | Persists in body after dosing |
| Metabolism | Hepatic | Liver function affects clearance |
| Elimination | Primarily biliary (fecal) | Enterohepatic circulation |
| Onset of ovulation induction | 5-10 days after last dose | Predictable ovulation timing |
| Duration of effect per cycle | One ovulatory cycle per treatment | Cycle-based therapy |
| Cumulative body accumulation | Zuclomiphene may accumulate | Long-term therapy considerations |
📏 Three Dose Strengths Advantage
Clomid Three Strength Comparison
| Strength | Primary Use | Patient Population |
|---|---|---|
| 25 mg | Sensitive patient starting dose or half-dose protocol | First-time users, sensitivity concerns |
| 50 mg | Standard first-line dose | Most anovulatory patients |
| 100 mg | First escalation dose for non-responders | Failed 50 mg cycle |
| 150 mg (100+50 combined) | Maximum recommended dose | Failed 100 mg cycle |
Dose Selection Framework
Clomid dose selection guide:
- 25 mg starting dose considered when: Very sensitive patients, elderly reproductive age, history of ovarian hyperstimulation, small body size, or specialist preference for gentle initiation
- 50 mg standard first-line: Most patients including standard PCOS, hypothalamic amenorrhea, and unexplained infertility empirical therapy
- 100 mg escalation: For patients not ovulating on 50 mg after adequate trial
- 150 mg maximum (100 + 50 combined): For patients not ovulating on 100 mg - last dose escalation before considering alternative therapies
🎯 FDA Approved Indications
Primary FDA Approved Indication
- Ovulatory dysfunction in women desiring pregnancy who otherwise would be candidates for pregnancy but ovulation is absent or infrequent
Broader Clinical Applications
- Stein-Leventhal Syndrome (PCOS) - historical name for polycystic ovary syndrome
- Secondary amenorrhea from various hormonal etiologies
- Oligomenorrhea - infrequent menstruation with cycles over 35 days
- Dysfunctional uterine bleeding from anovulatory hormonal imbalance
- Ovulation disorders in hypothalamic function deficiency (with adequate estrogen)
- Non-cancerous galactorrhea - selected use after pathology evaluation
- Chiari-Frommel Syndrome - post-partum amenorrhea-galactorrhea
Common Off-Label Uses
- Unexplained infertility with intrauterine insemination
- Male oligospermia - restore testosterone in secondary hypogonadism
- Luteal phase deficiency - inadequate corpus luteum function
- Superovulation for IUI - multiple follicle development
- Male hypogonadism - alternative to testosterone replacement therapy
Ideal Patient Selection
Clomid most appropriate for:
- Women with anovulatory infertility desiring pregnancy
- PCOS patients with normal male partner semen analysis
- Women with hypothalamic amenorrhea (adequate estrogen levels)
- Couples with unexplained infertility for empirical therapy
- Patients able to undergo cycle monitoring
- Women without contraindications to hormonal therapy
- Patients with intact hypothalamic-pituitary-ovarian axis
- Women accepting risk of multiple pregnancy (8-10 percent twins)
- Patients with adequate ovarian reserve
- Male patients with secondary hypogonadism (off-label use)
🚫 Contraindications and Precautions
Absolute Contraindications
- Pregnancy (Category X): Not for use during pregnancy - discontinue if pregnancy occurs
- Liver disease: Severe hepatic dysfunction contraindicated
- Undiagnosed abnormal uterine bleeding: Evaluate cause before therapy
- Ovarian cysts: Except polycystic ovaries in PCOS
- Uncontrolled thyroid dysfunction: Treat thyroid disease first
- Uncontrolled adrenal dysfunction: Treat adrenal disease first
- Pituitary tumor: Neurosurgical evaluation needed
- Hormone-sensitive cancers: Breast, endometrial, ovarian
- Visual disturbances from prior clomiphene use: Discontinue permanently
- Hypersensitivity to clomiphene or excipients
Precautions
Use with caution in:
- Advanced age: Reduced efficacy over age 35 due to diminished ovarian reserve
- Obesity: Reduced efficacy - weight loss improves response
- Depression history: Mood changes possible
- Endometriosis: May worsen symptoms
- Ovarian hyperstimulation history: Increased OHSS risk
- Multiple pregnancy concerns: 8-10 percent twin risk with clomiphene
- Visual symptoms: Discontinue if visual disturbances develop
- Ectopic pregnancy history: Slightly increased ectopic risk
💉 Dosage and Administration
Standard Dosing Protocol
Standard clomiphene dosing protocol:
- Starting dose: 50 mg once daily for 5 consecutive days (or 25 mg for sensitive patients)
- Cycle timing: Start on cycle day 3, 4, or 5 (day 1 = first day of menstruation)
- Continue for 5 days: Days 3-7, or 4-8, or 5-9
- Expected ovulation: Cycle days 14-16 (approximately 5-10 days after last dose)
- Timed intercourse: Every other day starting cycle day 10 through 18
- Ovulation confirmation: Basal body temperature, LH kits, or progesterone testing
Cycle Day Timing Protocol
| Cycle Day | Action | Purpose |
|---|---|---|
| Day 1 | First day of menstrual period | Cycle reference start |
| Day 3-5 | Start Clomid daily | Induce follicular development |
| Day 7-9 | Last Clomid dose | Complete 5-day course |
| Day 10-18 | Timed intercourse every other day | Cover ovulation window |
| Day 14-16 | Expected ovulation | LH surge triggers egg release |
| Day 21-22 | Progesterone level check | Confirm ovulation occurred |
| Day 28 or later | Pregnancy test if no menstruation | Assess conception |
Dose Escalation Using Three Available Strengths
Progressive dose escalation for inadequate response:
| Cycle | Dose | Tablet | Response Assessment |
|---|---|---|---|
| Cycle 1 | 50 mg x 5 days | 1 x 50 mg tablet | Confirm ovulation via progesterone |
| Cycle 2 if no ovulation | 100 mg x 5 days | 1 x 100 mg tablet | Escalation for non-response |
| Cycle 3 if no ovulation | 150 mg x 5 days | 1 x 100 mg + 1 x 50 mg | Maximum dose escalation |
| If ovulation but no pregnancy | Continue same effective dose | Same tablets | Up to 6 ovulatory cycles |
| If 150 mg fails | Discontinue clomiphene | N/A | Consider alternative therapies |
Maximum trial: 6 ovulatory cycles. Beyond this, consider alternative fertility therapies (letrozole, gonadotropins, IVF).
Administration Guidelines
- Take at consistent time each day during 5-day treatment cycle
- Swallow tablet whole with water
- Can take with or without food
- Do not skip doses during treatment cycles
- Report any visual disturbances immediately - permanent discontinuation required
- Track menstrual cycles carefully
- Confirm ovulation via basal body temperature, LH kits, or progesterone testing
- Time intercourse or IUI appropriately for ovulation window
- Pregnancy test if no menstruation by cycle day 28-30
- Discontinue immediately if pregnancy suspected
- Maintain regular follow-up with reproductive endocrinologist
📊 Clinical Effectiveness Data
| Metric | Response Data |
|---|---|
| Ovulation induction rate | 60-80 percent of appropriate patients |
| Pregnancy rate per cycle | 15-20 percent |
| Cumulative pregnancy rate (6 cycles) | 40-50 percent |
| Multiple pregnancy rate (twins) | Approximately 8-10 percent |
| Higher-order multiples | Rare (less than 1 percent) |
| Miscarriage rate | Comparable to natural pregnancy |
| Ovulation response at 50 mg | Approximately 50 percent of women |
| Ovulation response at 100 mg | Additional 25 percent respond |
| Ovulation response at 150 mg | Additional 10 percent respond |
| Clomiphene-resistant patients | Approximately 15-20 percent |
⚠️ Side Effects
Common Side Effects
- Hot flashes: Approximately 10 percent - most common side effect
- Ovarian enlargement: Approximately 14 percent
- Abdominal discomfort or bloating: Approximately 5 percent
- Breast tenderness: Common
- Nausea or vomiting: Approximately 2 percent
- Headache: Common
- Mood changes: Emotional lability, depression, anxiety
- Vaginal dryness: From antiestrogenic effects
- Endometrial thinning: Paradoxical antiestrogenic effect
- Cervical mucus thickening: May reduce sperm penetration
- Insomnia: Occasional
- Weight changes: Minor
Visual Disturbances Critical Warning
CRITICAL: Visual disturbances require immediate discontinuation
Clomiphene can cause visual disturbances that may become permanent if therapy continues. All patients must be aware of this critical safety concern.
Warning signs requiring immediate discontinuation:
- Blurred vision
- Spots or flashes in vision (scotoma)
- Double vision (diplopia)
- Light sensitivity (photophobia)
- Halos around lights
- Visual field defects
If any visual disturbances occur, discontinue Clomid immediately and consult ophthalmologist. Do not restart therapy - visual disturbances may become permanent with continued use.
Ovarian Hyperstimulation Syndrome (OHSS)
OHSS risk with clomiphene (rare):
- OHSS is rare with clomiphene compared to injectable gonadotropins
- Symptoms: severe abdominal pain, distension, nausea, vomiting
- Serious cases: fluid accumulation, kidney dysfunction, thromboembolism
- Higher risk with PCOS, higher doses, previous OHSS
- Requires immediate medical evaluation
Multiple Pregnancy Risk
Multiple pregnancy considerations:
- Twin pregnancy risk: Approximately 8-10 percent
- Higher-order multiples: Rare but possible (triplets or more)
- Increased pregnancy risks: Preterm birth, preeclampsia, gestational diabetes
- Neonatal considerations: Higher risk of prematurity complications
- Discuss with prescriber: Understand risks before starting therapy
- Ultrasound monitoring: Can identify multiple gestation early
Other Serious Adverse Events
Seek immediate medical attention for:
- Any visual disturbances: Discontinue immediately
- Severe abdominal pain: Possible OHSS or ovarian torsion
- Signs of ovarian torsion: Sudden severe unilateral pelvic pain
- Signs of ectopic pregnancy: Pelvic pain with positive pregnancy test
- Severe depression or mood changes
- Signs of allergic reaction: Rash, angioedema, difficulty breathing
- Signs of thromboembolism: Leg pain/swelling, chest pain, shortness of breath
- Severe headache with vision changes
- Signs of liver injury: Jaundice, dark urine, right upper pain
🔄 Drug Interactions
| Drug/Substance | Interaction |
|---|---|
| Ospemifene | Both SERMs - avoid concurrent use |
| Tamoxifen | Both SERMs - competing effects |
| Bexarotene | May reduce clomiphene efficacy |
| Danazol | Competing hormone effects |
| Gonadotropins (FSH, HCG) | Used in combination for ovulation induction protocols |
| GnRH agonists/antagonists | Complex interactions in ART protocols |
| Estrogen supplements | May counteract clomiphene antiestrogenic action |
| Metformin | Combined use in PCOS may enhance response |
| Corticosteroids | Sometimes used adjunctively in PCOS treatment |
| Bromocriptine or cabergoline | For concurrent hyperprolactinemia management |
🛡️ Special Populations
- Reproductive Age Women
- Standard indication population. Comprehensive fertility workup required before therapy. Reproductive endocrinology supervision recommended. 50 mg standard starting dose appropriate for most patients.
- Pregnancy (Category X)
- ABSOLUTELY CONTRAINDICATED during pregnancy. Discontinue immediately if pregnancy suspected. Rule out pregnancy before each cycle initiation. Not for use if any doubt about pregnancy status.
- Lactation
- Not indicated during breastfeeding as it may reduce milk production. Complete lactation before fertility therapy for next pregnancy attempts.
- PCOS Patients
- Primary indication population. First-line therapy for PCOS-related anovulatory infertility. Weight loss adjunct improves response. Metformin combination may enhance efficacy in insulin-resistant patients. Standard 50 mg starting dose typical.
- Sensitive Patients
- 25 mg starting dose available for sensitive patients, elderly reproductive age, small body size, or history of ovarian hyperstimulation. Enables gentle initiation with escalation as needed.
- Obese Patients
- Reduced clomiphene efficacy with obesity. Weight loss of 5-10 percent may substantially improve ovulation rates. Consider weight management strategies before or during therapy.
- Advanced Reproductive Age (Over 35)
- Diminished ovarian reserve affects response. Consider ovarian reserve testing (AMH, AFC, FSH). Reduced overall fertility success rates. May proceed more quickly to alternative therapies.
- Hypothalamic Amenorrhea Patients
- Requires adequate estrogen production for clomiphene response. If hypoestrogenic, clomiphene may not be effective. Consider gonadotropin therapy for hypothalamic hypogonadism.
- Depression History
- May worsen mood symptoms. Monitor for mood changes throughout therapy. Consider mental health support during fertility treatment.
- Endometriosis Patients
- May worsen endometriosis symptoms. Consider treatment of endometriosis before or with fertility therapy. Reproductive endocrinology consultation essential.
- Male Hypogonadism (Off-Label)
- Off-label use to restore testosterone in secondary hypogonadism. Increases endogenous testosterone through hypothalamic-pituitary stimulation. Requires urologist or endocrinologist supervision.
- Prior Ovarian Surgery Patients
- Assess ovarian reserve and function. May have reduced response depending on surgery extent. Consider ovarian reserve testing.
- Diabetic Patients
- Ensure adequate diabetes control before pregnancy attempts. Pre-pregnancy folic acid supplementation. Coordination with endocrinology for optimal glycemic control.
🔄 When Clomiphene Fails
Alternative therapies when clomiphene fails:
- Letrozole (Femara): Aromatase inhibitor - first-line PCOS alternative in modern practice
- Gonadotropins (FSH, HMG): Injectable ovulation induction with more precise control
- Metformin combination: Add to clomiphene for insulin-resistant PCOS
- Ovarian drilling: Laparoscopic surgical option for clomiphene-resistant PCOS
- Intrauterine insemination (IUI): With clomiphene or gonadotropins for unexplained infertility
- In vitro fertilization (IVF): Advanced reproductive technology for treatment-resistant infertility
- Weight loss: Substantially improves fertility in obese patients
- Address underlying conditions: Thyroid, prolactin, adrenal disorders
📆 Long-Term Follow-Up
Long-term therapy considerations:
- Regular reproductive endocrinology follow-up: Cycle-by-cycle assessment
- Maximum 6 ovulatory cycles: Beyond this consider alternative therapies
- Ovarian cancer surveillance: Some evidence of increased risk with more than 12 cycles
- Endometrial monitoring: Ultrasound assessment given antiestrogenic effects
- Pregnancy planning: Prenatal counseling before pregnancy attempts
- Folic acid supplementation: Standard preconception vitamin
- Diabetes screening: Particularly for PCOS patients
- Cardiovascular assessment: PCOS carries cardiovascular risk factors
- Weight management: Ongoing lifestyle intervention
📦 Storage and Handling
- Store at room temperature between 15°C and 30°C (59°F and 86°F)
- Protect from light, moisture, and heat
- Keep tablets in original packaging
- Keep out of reach of children and pets
- Do not use past expiration date
- Do not share medication with others
- Return unused medication to pharmacy for proper disposal
👨⚕️ When to Contact Your Doctor
- Any visual disturbances - discontinue immediately and seek ophthalmology evaluation
- Severe abdominal pain - possible OHSS or ovarian torsion
- Signs of ovarian torsion: sudden severe unilateral pelvic pain
- Signs of ectopic pregnancy: pelvic pain with positive pregnancy test
- Severe depression or suicidal thoughts
- Signs of allergic reaction: rash, angioedema, difficulty breathing
- Signs of thromboembolism: leg pain/swelling, chest pain, shortness of breath
- Severe headache with vision changes
- Signs of liver injury: jaundice, dark urine, right upper pain
- Suspected pregnancy - discontinue immediately
- Absence of menstruation - pregnancy test needed
- Failure to ovulate after cycle - dose escalation discussion
- Multiple pregnancy identified on ultrasound
- Any concerning symptoms during treatment
- Time for scheduled monitoring appointments
- Consideration of dose escalation or alternative therapy
🌟 Key Takeaways
Essential points about Clomid therapy:
- Clomid is Cipla or Sunrise Remedies generic clomiphene citrate in 25/50/100 mg tablets
- Original Merrell Dow/Sanofi brand identity - FDA-approved 1967
- Over 55 years of continuous clinical use as first-line ovulation induction therapy
- Selective Estrogen Receptor Modulator (SERM) established the pharmacological class
- Three dose strengths (25/50/100 mg) enable precise individualized dosing
- Standard 50 mg starting dose with escalation via 100 mg or 100+50 mg (150 mg)
- Works through hypothalamic estrogen receptor antagonism
- Increases GnRH pulsatility, FSH, and LH stimulating ovarian follicular development
- First-line therapy for PCOS-related anovulatory infertility
- Dosing: 50 mg daily for 5 days starting cycle day 3-5
- Expected ovulation cycle days 14-16
- Maximum 6 ovulatory cycles typical trial
- 60-80 percent ovulation induction rate, 40-50 percent cumulative pregnancy over 6 cycles
- Approximately 8-10 percent twin pregnancy risk
- CRITICAL: Any visual disturbances require immediate discontinuation
- Pregnancy Category X - contraindicated during pregnancy
- Contraindicated in liver disease, ovarian cysts, pituitary tumor, hormone-sensitive cancers
- Common side effects: hot flashes, ovarian enlargement, breast tenderness, mood changes
- Requires reproductive endocrinology supervision
- Cycle monitoring recommended (BBT, LH kits, progesterone, ultrasound)
- Alternative therapies if clomiphene fails: letrozole, gonadotropins, IVF
Important Medical Disclaimer: This medication guide provides general information about Clomid (Cipla or Sunrise Remedies generic clomiphene citrate 25/50/100 mg tablets) and does not constitute individualized medical advice. Every patient situation is unique and requires comprehensive fertility evaluation by a reproductive endocrinologist or fertility specialist before starting therapy. Clomid is the original Sanofi brand identity for clomiphene citrate with over 55 years of clinical use. Three dose strengths enable precise individualized dosing across full clinical range. Clomiphene therapy requires cycle-by-cycle monitoring with ovulation confirmation and progression assessment. Pregnancy Category X - absolutely contraindicated during pregnancy. Rule out pregnancy before each cycle initiation. CRITICAL: Any visual disturbances require immediate discontinuation and ophthalmology evaluation - do not restart therapy as visual disturbances may become permanent. Contraindicated in liver disease, undiagnosed abnormal uterine bleeding, ovarian cysts (except PCOS), pituitary tumor, hormone-sensitive cancers, and prior visual disturbances from clomiphene. Report severe abdominal pain (possible OHSS or ovarian torsion), suspected ectopic pregnancy, severe depression, allergic reactions, or thromboembolism signs immediately. Multiple pregnancy risk approximately 8-10 percent twins requires discussion before therapy initiation. Maximum 6 ovulatory cycles recommended - beyond this consider alternative fertility therapies including letrozole, gonadotropins, or in vitro fertilization. Coordinate care with reproductive endocrinologist for optimal fertility outcomes. If you experience concerning symptoms contact your healthcare provider promptly. The information provided here should complement but never replace direct professional medical guidance from your fertility specialist.
Clomid — Frequently Asked Questions
-
What is Clomid?
Clomid, or clomiphene citrate, is a medication prescribed to stimulate ovulation in women experiencing infertility due to problems with ovulation. -
How does Clomid work?
It works by stimulating the release of hormones necessary for ovulation to occur, primarily by blocking estrogen receptors, which increases the production of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). -
Who should take Clomid?
Clomid is typically prescribed for women with ovulatory disorders like PCOS or those who have unexplained infertility and have not been able to conceive naturally. -
How is Clomid taken?
Clomid is taken orally, usually starting on the third to the fifth day of the menstrual cycle, for five consecutive days. -
What dosage of Clomid is usually prescribed?
The starting dose is often 50 mg daily, but this can be adjusted based on the individual's response to the medication. -
How long does it usually take to ovulate after taking Clomid?
Most women ovulate about 7 to 10 days after completing a course of Clomid. -
Can Clomid increase the chance of twins?
Yes, Clomid can increase the likelihood of conceiving twins, usually up to a 10% chance, due to the stimulation of multiple follicles.
More Women's Health Medications
